Renalytix Appoints Jean M. Casner as Chief Human Resources Officer
NEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice President & Chief Human Resources Officer. Ms. Casner will be responsible for Renalytix’s global human resources organization, including people strategy, compensation, benefits, learning and development, diversity & inclusion, and performance and talent management.
Ms. Casner joins Renalytix from her former position as Senior Vice President & CHRO at Cantel Medical, which experienced significant annual revenue growth during her tenure prior to the company being recently acquired. During her time at Cantel, she made significant contributions to the company, including creating and implementing a global compensation and benefits strategy, developing and executing a refreshed annual incentive plan as part of Cantel’s total rewards strategy and implementing a global learning platform. Prior to Cantel, she held HR leadership positions at the National Basketball Association (NBA), Merck, The Dial Corporation (now owned by Henkel), Johnson and Johnson and ORC (now owned by Mercer). Ms. Casner succeeds Trent Bingham who departed Renalytix on December 31, 2021.
With a lifelong focus and passion for healthcare, Ms. Casner has been recognized for her ability to grow companies and implement robust training, learning and development strategies, with a focus on employee engagement and transparent leadership.
“Defining and supporting employee culture during a high-growth phase is complex and utterly critical to business execution,” said James McCullough, CEO, Renalytix. “Jean brings the deep experience that will allow Renalytix to expand the skilled personnel required to support our growing base of healthcare system partnership customers and their doctors and patients, as we continue to execute on what we believe will be significant commercial and revenue expansion in the years ahead.”
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer.2 Every day, 13 patients in the United States die while waiting for a kidney transplant.3
About Renalytix
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers and personalized data from the patient’s health record, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in DKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
Sources
1 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
2 https://www.nicresearch.com/clinical-research-necessary-nephrology/
3 https://optn.transplant.hrsa.gov/
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits, including economic savings, of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC on October 21, 2021, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
UK Investor Contact:
Walbrook PR Limited
Paul McManus / Lianne Applegarth
Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303
US Investor Contact:
CapComm Partners
Peter DeNardo
investors@renalytix.com
415-389-6400
Media Contacts:
United States:
Chloe Beaudoin
Renalytix
(207) 333-7947
cbeaudoin@renalytix.com
Outside of the United States:
Walbrook PR Limited
Paul McManus / Lianne Applegarth
Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303
